DESIGN FOR FDA: A PREDICTIVE MODEL FOR THE FDA'S DECISION TIME FOR MEDICAL DEVICES

The concept of Design for FDA (DfFDA) has a strong basis on the Food and Drug Administration’s (FDA) regulation for medical devices in the Unites States. In fact; an analysis of the factors that impact the time it takes the FDA’s to provide market approval for medical devices, the product design process model, and Design for X (DfX) methods with overlapping FDA objectives lead to the development of DfFDA as a means to increase awareness about regulatory compliance and promote designers to consider the regulations throughout the development process of medical devices. For doing so, the main objective of DfFDA is to provide regulation-focused guidelines to producers of medical devices. An important part of these guidelines and this paper’s major contribution is the development of a prediction model for the FDA’s decision time. Overall, we want this model to become a tool that allows medical device companies to come up with an accurate estimate of a product’s time-to-market after accounting for the FDA’s decision time. In this work, we provide a comparison and discussion on the adequacy of linear regression models and other non-linear models such as parallel and serial tree-based ensembles for prediction the FDA’s decision time.

[1]  Mohan V. Tatikonda,et al.  Technology novelty, project complexity, and product development project execution success: a deeper look at task uncertainty in product innovation , 2000, IEEE Trans. Engineering Management.

[2]  A. Griffin The Effect of Project and Process Characteristics on Product Development Cycle Time , 1997 .

[3]  David Wilemon,et al.  An empirical investigation of complexity and its management in new product development , 2009, Technol. Anal. Strateg. Manag..

[4]  Jack E. Lemons,et al.  New Products and Standards , 1996 .

[5]  Achim Zeileis,et al.  Conditional variable importance for random forests , 2008, BMC Bioinformatics.

[6]  Abbie Griffin,et al.  Modeling and measuring product development cycle time across industries , 1997 .

[7]  P. Murmann Expected development time reductions in the German mechanical engineering industry , 1994 .

[8]  Gül E. Okudan Kremer,et al.  An Analysis of Critical Factors in Medical Device Development to Design for FDA , 2012 .

[9]  S. Bartlett Foote Medical technology development: limiting regulation , 1996 .

[10]  A. Griffin Metrics for Measuring Product Development Cycle Time , 1993 .

[11]  Shelby D. Reed,et al.  Economic Implications of Potential Changes to Regulatory and Reimbursement Policies for Medical Devices , 2007, Journal of General Internal Medicine.

[12]  Achim Zeileis,et al.  Bias in random forest variable importance measures: Illustrations, sources and a solution , 2007, BMC Bioinformatics.

[13]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[14]  Lourdes A. Medina,et al.  A Review of Design for X Methods for Medical Devices: The Introduction of a Design for FDA Approach , 2011 .

[15]  George C. Runger,et al.  Feature Selection with Ensembles, Artificial Variables, and Redundancy Elimination , 2009, J. Mach. Learn. Res..

[16]  Buddy D. Ratner,et al.  Biomaterials Science: An Introduction to Materials in Medicine , 1996 .

[17]  Ian Robinson,et al.  Benefits of and barriers to involving users in medical device technology development and evaluation , 2007, International Journal of Technology Assessment in Health Care.

[18]  Philip H Long,et al.  Medical Devices in Orthopedic Applications , 2008, Toxicologic pathology.

[19]  J. Friedman Greedy function approximation: A gradient boosting machine. , 2001 .

[20]  Kannan Srinivasan,et al.  New product development structures and time-to-market , 1997 .

[21]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[22]  Michael Simons,et al.  Medical Device Development: From Prototype to Regulatory Approval , 2004, Circulation.

[23]  John Hutton,et al.  Regulating the economic evaluation of pharmaceuticals and medical devices: a European perspective. , 2003, Health policy.

[24]  M. R. Millson,et al.  Managing innovation in the medical device industry , 1998, IEMC '98 Proceedings. International Conference on Engineering and Technology Management. Pioneering New Technologies: Management Issues and Challenges in the Third Millennium (Cat. No.98CH36266).

[25]  K. B. Hendricks,et al.  Delays in new product introductions and the market value of the firm: the consequences of being late to the market , 1997 .

[26]  David Anderson,et al.  Proving experience speeds medical device time to market , 2009, 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.